newsfilter
← Latest News
GlobeNewswire·

Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

SCTX
  • Initiated the first-in-human Phase 1 trial of STX-1150, an epigenetic silencing therapy for LDL-C lowering, in Australia using the ELXR technology to repress PCSK9 without permanent DNA changes.
  • Awarded over $25 million in CIRM grants to advance STX-1200 for Lp(a) lowering & STX-1400 for triglyceride lowering toward clinical entry in 2027.
  • Completed an upsized IPO with full underwriter option exercise & a concurrent private placement to Sanofi, generating approximately $155.5 million in aggregate gross proceeds.
  • Reported a cash position of $43.0 million as of June 30, 2026, combined with $140.6 million in net IPO proceeds to fund operations into the first half of 2029.
  • Advanced STX-1150 with preclinical data showing up to 90% PCSK9 silencing & LDL-C reductions of 68% in non-human primates, with durable effects lasting two years.
  • Awarded $12.7 million for STX-1200 to target LPA via XE technology, achieving >95% Lp(a) reduction in preclinical studies.
  • Awarded $13.0 million for STX-1400 to target APOC3 via XE technology, achieving >75% on-target editing in preclinical studies to address severe hypertriglyceridemia.
  • Published bioRxiv findings on ELXR platform enhancements demonstrating up to 10x reduction in off-target effects & 4x increase in on-target activity.
  • Reported second quarter 2026 financial results showing $1.9 million in collaboration revenue, $8.8 million in R&D expenses, & a net loss of $6.5 million.
  • Listed common stock on the Nasdaq Global Market under ticker "SCTX" beginning July 24, 2026, at a price of $15.00 per share.